Zealand Pharma's Annual General Meeting 2024
21 March 2024 - 3:39AM
UK Regulatory
Zealand Pharma's Annual General Meeting 2024
Company announcement – No. 17 / 2024
Zealand Pharma's Annual General Meeting
2024
Copenhagen, March 20, 2024 - Today,
Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50
78), held its Annual General Meeting of 2024 as a partly electronic
and partly physical general meeting (hybrid meeting).
At the meeting, all proposals presented to the
General Meeting were adopted.
The General Meeting acknowledged the
management's report on Zealand's activities in the past financial
year and Zealand's audited Annual Report for 2023 was approved. The
meeting also approved that the financial result for 2023, which was
a loss of TDKK 703,739, was carried forward to the next financial
year.
The following members were re-elected to the
Board of Directors as recommended by the Nomination Committee:
- Alf Gunnar Martin Nicklasson
- Kirsten Aarup Drejer
- Jeffrey Berkowitz
- Leonard Kruimer
- Bernadette Mary Connaughton
Further, the following were elected as new
members of the Board of Directors in accordance with the
recommendation of the Nomination Committee (replacing Alain Munoz
and Michael John Owen who did not stand for re-election):
- Elaine Sullivan
- Enrique Conterno Martinelli
After the Annual General Meeting, the
Board of Directors constituted itself with Martin Nicklasson and
Kirsten Aarup Drejer continuing as the Chair and the Vice-Chair,
respectively.
The Audit Committee will comprise Martin
Nicklasson, Bernadette Mary Connaughton, and Jeffrey Berkowitz,
with Leonard Kruimer chairing the Committee.
The Remuneration Committee will compromise
Enrique Conterno Martinelli and Leonard Kruimer, with Martin
Nicklasson chairing the Committee.
The Scientific Committee will compromise Elaine
Sullivan and Enrique Conterno Martinelli, with Kirsten Aarup Drejer
chairing the Committee.
The Nomination Committee will compromise Leonard
Kruimer and Martin Nicklasson, with Kirsten Aarup Drejer chairing
the Committee.
The Board of Directors also consists of the
employee-elected members Anneline Nansen, Nikolaj Frederik Beck,
Adam Krisko Nygaard, and Ludovic Tranholm Otterbein who had been
elected for the period until 2028.
PricewaterhouseCoopers Statsautoriseret
Revisionspartnerselskab (PwC) was elected as Zealand's new auditor
for both financial and sustainability reporting purposes as
proposed by the Board of Directors in accordance with the
recommendation of the Audit Committee.
The Board of Directors was authorized to allow
Zealand to acquire, in the period until the next Annual General
Meeting, treasury shares directly for a nominal value of up to 10%
of Zealand's share capital from time to time.
Zealand's revised Remuneration Policy and the
Remuneration Report presented under agenda items 7 and 8,
respectively, were approved by the General Meeting as proposed by
the Board of Directors.
The fees for the Board of Directors for the
financial year 2024 presented under agenda item 9 were approved by
the General Meeting. The fees remain unchanged compared to
2023.
The Board of Directors was authorized to
increase the share capital of Zealand during the period until 20
March 2029 by way of cash contribution up to an aggregate amount of
nominally DKK 12,500,000 at market price and without pre-emption
rights for the existing shareholders. The new authorization
replaces the existing authorization set forth in Article 7.1 of the
Company's Articles of Association. Further, the existing
authorization for the Board of Directors to issue warrants pursuant
to Articles 8.10 - 8.13 of the Company's Articles of Association
was extended by one year until 20 March 2029 and increased by
nominally DKK 767,687. The total number of warrants available for
issuance under this authorization is hereinafter 2,500,000.
Finally, the General Meeting approved the
introduction of an indemnification scheme for the Board of
Directors and Executive Management of the Company as proposed by
the Board of Directors and presented under agenda item 12.
Zealand Pharma A/S
The Board of Directors
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology
company focused on the discovery and development of peptide-based
medicines. More than 10 drug candidates invented by Zealand have
advanced into clinical development, of which two have reached the
market and three candidates are in late-stage development. The
company has development partnerships with a number of pharma
companies as well as commercial partnerships for its marketed
products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. For information about
Zealand’s business and activities, please
visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate
Communications
Zealand Pharma
Email: ank@zealandpharma.com
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Sep 2024 to Oct 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Oct 2023 to Oct 2024